Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2012

View Archived Issues

Novartis reports novel CDK9 inhibitors

First prenatal replacement therapy presented for rare form of dystonia

Biotherapy demonstrates activity relevant to multiple sclerosis

New in vivo data disclosed on monomethylfumarate prodrug for MS

ETS-2101 trial in brain cancer begins enrollment

German group discloses new agents for dermatological disorders

Novel products for tuberculosis designed at Sanofi

AstraZeneca stops AZD-2820 study

Novel agents for AIDS prepared at Pfizer

Canadian study investigates microglial activation in patients with PD

Phase III crizotinib study meets endpoint

NewLink updates enrollment information for algenpantucel-L trial

Galaxy Biotech regains worldwide rights to antibody for cancer

Zalicus completes phase I study of Z-944

Novelos reports imaging results with [124I]-CLR-1404 in brain cancer

Investigational gene therapy gets orphan drug status for adrenoleukodystrophy

Jenrin Discovery develops new agents targeting CB1 receptor

AstraZeneca and Rigel sign worldwide licensing agreement for asthma drug

French center synthesizes new agents for bone disorders

Team in Israel patents new treatments for genetic disorders

Vaxin receives phase I SBIR grant to support development of anthrax vaccine

Wellcome Trust supports development of nontyphoidal Salmonella conjugate vaccine

EMA validates MAAs for fixed-dose combination diabetes therapies

First clinical data disclosed on Genzyme DNA topoisomerase I inhibitor

EpiCept sells European rights for Ceplene to Meda

Viamet and NIAID enter agreement to advance new class of broad-spectrum antifungals

Novel candidate hepatitis therapies divulged by Gilead Sciences

Heptares and U.K. Medical Research Council extend collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...